20/100 · Low Risk
Manufactured by Boiron
Low Report Volume for Eucalyptus Globulus Leaf
Last updated: 2026-05-12
EUCALYPTUS GLOBULUS LEAF is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Boiron. Based on analysis of FDA adverse event reports, EUCALYPTUS GLOBULUS LEAF has a safety score of 20 out of 100. This lower score reflects a significant number of adverse event reports, suggesting that patients should discuss potential risks carefully with their healthcare provider. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for EUCALYPTUS GLOBULUS LEAF.
Eucalyptus Globulus Leaf has a safety concern score of 20 out of 100, placing it in the low concern category based on analysis of FDA adverse event data. The FDA has received approximately N/A adverse event reports for this medication, which is primarily manufactured by Boiron.
Of classified reports, 81.0% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. No serious adverse events reported.
All reported events are non-serious. Only one serious event reported out of 21 total reports.
Patients taking Eucalyptus Globulus Leaf should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Eucalyptus Globulus Leaf received a safety concern score of 20/100 (low concern). This is based on a 81.0% serious event ratio across 21 classified reports. The score accounts for N/A total adverse event reports and 0 distinct reaction types. This relatively low score suggests a favorable safety profile in reported data.
The most frequently reported age groups are age 50 (3 reports), age 74 (3 reports), age 77 (3 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 21 classified reports for EUCALYPTUS GLOBULUS LEAF:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
If you are taking Eucalyptus Globulus Leaf, here are important things to know. Monitor for any unusual symptoms after use. Consult a healthcare provider if symptoms persist. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA has received approximately N/A adverse event reports associated with Eucalyptus Globulus Leaf. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
Out of 21 classified reports, 17 (81.0%) were classified as serious and 4 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
The most frequently reported age groups for Eucalyptus Globulus Leaf adverse events are: age 50: 3 reports, age 74: 3 reports, age 77: 3 reports, age 66: 2 reports, age 15: 1 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Eucalyptus Globulus Leaf adverse event reports is Boiron. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
You can report adverse events from Eucalyptus Globulus Leaf to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Eucalyptus Globulus Leaf has a safety concern score of 20 out of 100 (low concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. No serious adverse events reported.
Key safety signals identified in Eucalyptus Globulus Leaf's adverse event data include: Single serious event reported.. Low report volume limits data analysis.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Monitor for any unusual symptoms after use. Consult a healthcare provider if symptoms persist.
Eucalyptus Globulus Leaf has N/A adverse event reports on file with the FDA. All reported events are non-serious. The volume of reports for Eucalyptus Globulus Leaf reflects both the drug's usage level and the vigilance of the reporting community.
Explore other medications manufactured by Boiron and compare their safety profiles:
Drugs related to EUCALYPTUS GLOBULUS LEAF based on therapeutic use, drug class, or shared indications: